Pfizer ’s Latest Acquisition Strengthens the Case for PFE Stock

The gold catalyst we’ve waited for (From Stansberry Research) On March 13, 2023, Pfizer, Inc. (NYSE: PFE) announced it was merging with Seagen Inc. (NASDAQ: SGEN). Under terms of the definitive agreement, Pfizer will buy Seagen for $229 in cash per share. That makes the total enterprise value $43…#stansberryresearch #pfizerinc #pfe #seageninc #pfizer #seagen #merckco #mrk #mercks #merck
Source: Reuters: Health - Category: Consumer Health News Source Type: news